News / Taiwan / economic_daily
Taiwan Innovation Board Boosts Biotech Sector with Focus on Precision Health
Health Technology · Biotechnology · economic_daily · 2026-08-21
The Taiwan Innovation Board is accelerating the capitalization of the precision health sector by supporting startups in AI diagnostics, genomics, and cell therapy.
What Happened
Capitalizing the Biotech Sector: The Taiwanese biotech industry is experiencing a surge in public listings, supported by a clearer regulatory environment and strong clinical validation. The Taiwan Innovation Board (TIB) utilizes a market-cap-centric evaluation framework to help precision health startups secure long-term institutional capital before full-scale commercialization.
Regulatory and Policy Support: Government initiatives, including the Statute for Industrial Innovation and new AI medical guidelines, provide a robust framework for industry growth. As the legal landscape for AI in healthcare matures, Taiwan is positioning itself as a hub for innovation by balancing regulatory certainty with operational flexibility.
Strategic Evaluation Framework: The TWSE has implemented a specialized assessment model for biotech firms, focusing on patent portfolios, clinical trial milestones, and the scalability of technology platforms. Chairman Lin Hsiu-ming emphasizes that this approach bridges the gap between R&D and capital markets, allowing companies to articulate their growth stories effectively.
Targeting Key Growth Sectors: The TIB is prioritizing four key areas: AI-assisted diagnostics, precision medicine and genomics, regenerative medicine, and digital health. These sectors align with global trends in precision health and offer significant potential for market expansion and technological integration.